2013
DOI: 10.3171/2013.7.jns1323
|View full text |Cite
|
Sign up to set email alerts
|

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis

Abstract: Object. Recurrent malignant gliomas have inherent resistance to traditional chemotherapy. Novel therapies target specific molecular mechanisms involved in abnormal signaling and resistance to apoptosis. The proteasome is a key regulator of multiple cellular functions, and its inhibition in malignant astrocytic lines causes cell growth arrest and apoptotic cell death. The proteasome inhibitor bortezomib was reported to have very good in vitro activity against malignant glioma cell lines, with modest activity in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
50
0
1

Year Published

2014
2014
2021
2021

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 55 publications
(51 citation statements)
references
References 33 publications
0
50
0
1
Order By: Relevance
“…Consequently, finding new agents to integrate into standard treatment for newly-diagnosed GBM is required to improve patient survival. Bortezomib is an FDA approved proteasome inhibitor for hematologic malignances that has shown efficacy towards GBM cell lines in vitro and in vivo (7–8, 1415). Therefore, we sought to gain a greater insight into the use of bortezomib as a treatment for newly-diagnosed GBM patients, by combining it into current standard of care and examined its efficacy as well as safety.…”
Section: Discussionmentioning
confidence: 99%
“…Consequently, finding new agents to integrate into standard treatment for newly-diagnosed GBM is required to improve patient survival. Bortezomib is an FDA approved proteasome inhibitor for hematologic malignances that has shown efficacy towards GBM cell lines in vitro and in vivo (7–8, 1415). Therefore, we sought to gain a greater insight into the use of bortezomib as a treatment for newly-diagnosed GBM patients, by combining it into current standard of care and examined its efficacy as well as safety.…”
Section: Discussionmentioning
confidence: 99%
“…Among the cellular processes that are critical for glioblastoma pathology, protein degradation is emerging as an important regulator of tumorigenesis and a target for cancer treatment (13)(14)(15). Ubiquitination and its reverse, deubiquitination, are major regulatory pathways that control protein degradation and contribute to cell-cycle regulation, stem cell maintenance, and cellular survival, as well as other biologic activities of importance for tumorigenesis (16,17).…”
Section: Introductionmentioning
confidence: 99%
“…Recent studies suggest that PIs can also induce apoptosis in human glioma cell lines and primary glioblastoma multiforme (GBM) explants . PIs were also shown to induce apoptosis in glioma‐derived stem‐like cells . In a recent siRNA screening to identify genes important for GBM cell survival, 22% (12/55) of the hits were components of the 20S and 26S proteasome subunits .…”
Section: Introductionmentioning
confidence: 99%